Covid19cle

09/22/2023

Stay Up to Date with COVID-19 Vaccines

What You Need to Know
• CDC recommends the 2023–2024 updated COVID-19 vaccines.
• Everyone aged 5 years and older should get 1 dose of the updated Pfizer-BioNTech or Moderna COVID-19 vaccine to protect against serious illness from COVID-19.
• People who are moderately or severely immunocompromised may get additional doses of updated COVID-19 vaccine.
• Children aged 6 months–4 years need multiple doses of COVID-19 vaccines to be up to date, including at least 1 dose of updated COVID-19 vaccine.
• COVID-19 vaccine recommendations will be updated as needed.

COVID-19 vaccines protect against COVID-19. Get safety info and more.

05/02/2023

Good news on COVID-19 numbers, but it's STILL a thing, and we encourage you to get your 2nd booster (or 1st, if you haven't done that yet).

If you have a very recent case of COVID-19, we would love to tell you about our observational Continuum study (no medicine). Compensation provided. 216-844-4444 / info@case.edu

The number of COVID-19 patients in Ohio hospitals fell from 395 last week to 322 on Thursday. That number is below a recent high of 1,423 on Dec. 29.

02/09/2023

Intriguing news about for COVID-19 treatment...

Approving this drug would double our COVID treatment options, says Dr Perry Wilson in this week's Impact Factor.

01/31/2023

An average of more than 500 people in the US are still dying from Covid-19 each day, but....

The end of the emergency, planned for May 11, will bring about a complex set of policy changes and signals a new chapter in the government’s pandemic response.

12/21/2022

We have solid tools to prevent COVID-19 (vaccines, masks, fresh air, distancing, shorter parties), but if you end up with a positive test after holiday socials, please consider volunteering for our observational research study, Continuum. Compensation provided. 💜

09/30/2022

Congratulations and many thanks to our CAB member and good friend Jan Kosmyna on being elected to co-chair the AIDS Clinical Trials Group Global Community Advisory Board (GCAB)! 💜

Jan Kosmyna, MIS, B.Ed., RN

Pre-retirement, Jan held multiple research positions, including research nurse in oncology, then HIV/AIDS, AIDS Clinical Trials Group (ACTG) clinical site coordinator at the University of Toledo Medical Center, project director, Wayne State University HIV/AIDS Research Program, held several clinical positions in the pharmaceutical industry, served as research subject advocate and IRB member, University of Michigan Medical Center, community research manager, and volunteer member of the Case Western Reserve University/University Hospitals Cleveland Community Advisory Board. She also served on multiple research committees and protocol teams in the former Community Programs for clinical research on AIDS.

Jan has more recently served on the ACTG Community Science Subcommittee (CSS), Site Management and Clinical Care Subcommittee, CSS New Members Subcommittee, Executive Committee, Performance Evaluation Committee, Antiretroviral Strategies Committee, and multiple protocol teams, including the ACTIV-2 COVID-19 Adaptive Platform study and also is a representative on the ACTG COVID CAB. Beginning on 10/1/22, she takes on the role of co-chair of the ACTG Global Community Advisory Board.

09/26/2022

COVID-19 is still a global pandemic, despite what the president says. If you have a recent case (last 10 days), please consider volunteering for an observational study with us. Compensation provided. Call 216-844-4444. Thank you.

09/20/2022

Please join us Thursday evening at Lutheran Hospital in Ohio City for a community health fair, open to ALL! We'll have a table there with information about our HIV, COVID-19, and monkeypox studies. 💜

09/14/2022

“Covid-19 is the third-leading cause of death in the United States. And it’s as if we’ve just accepted that that is going to be the case.”

BE BETTER: GET YOUR BIVALENT COVID-19 SHOT!

The agency cleared two options aimed at subvariants that are now dominant, hoping to curtail a fall or winter surge.

08/24/2022

COVID-19 is still killing 462 people in the US every day. If you have a recent positive test, please call us at 216-844-4444 to hear about our observational (no drugs) Continuum study. Your close contacts who are not infected are also eligible for the study.

08/24/2022

Long-COVID and HIV study

The only clinical study in the US dedicated to understanding the long-term effects of COVID-19 in People Living with HIV (PLHIV) still needs eligible participants and the enrollment window ends on September 30!

Therefore, Strategies for High Impact and its Network for Long COVID Justice continue their urgent call to share the study’s enrollment information (also available in Spanish).

Amidst the latest surge driven by the BA.5 variant, more people living with HIV are getting COVID-19 for the first time in recent weeks. Their experience is crucial to learn more about the long term effects of COVID-19 on PLHIV!

This is an important research study, supported by amfAR, that is open to anyone living with HIV:

--who has had COVID-19 for the first time within 4 weeks of enrollment

Or
--has never had COVID-19

They will send someone to you to take blood samples, and there is compensation for your time (up to $75-$100).

The study is fully remote, and all study events can be completed from home! Please share this information with your networks, organizations, staff, constituents, service users or members.

To learn more about HIV, COVID-19 and Long COVID, get our NEW REPORT : bit.ly/HIVreport.

Details on the study, compensation, and inclusion criteria:

It can’t be emphasized enough: This is the only clinical study in the US dedicated to understanding the long term effects of COVID-19 in People Living with HIV!

Initial studies have suggested that PLHIV may be at higher risk of Long COVID, which can happen even after mild or asymptomatic cases of COVID-19. So it is vital to learn more about what this can mean for PLHIV. It could also have far-reaching implications in the management and treatment of Long COVID symptoms or all people, regardless of serostatus.

In addition to making an invaluable contribution to the HIV community’s well being, participants may be compensated up to $75-$100 (in 3 or 4 installments of $25) for completing each of the study’s requirements: 1 phone screening, 2 online questionnaires/surveys, and 1 or 2 blood draws (approx 3 tbsp) 3 months apart.

All visits are conducted in the comfort of the participant’s home, or another suitable and convenient location of the participant’s choice as follows:

HIV+ adults with recent COVID-19 diagnosis
Required study events:
--Baseline questionnaire at enrollment or month 1.
--Follow-up questionnaire at month 1 and month 4
--Height, weight, vital signs, and blood sampling at month 1 and month 4
Optional study events:
--Follow-up questionnaire at month 2, month 6, and month 12

HIV+ adults with no history of COVID-19
Required study events:
--Baseline questionnaire at enrollment.
--Follow-up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.
--Height, weight, vital signs, and blood sampling at enrollment.

Optional study events:
--Follow-up questionnaire at 1, 5, and 11 months after first follow-up questionnaire.

Blood samples will consist of no more than 50 ml (approx 3 tbsp) and will be obtained at different points in the study’s timeline—about 3 months apart. Participants can withdraw from the study at any point, should they wish to do so.

Confidentiality is paramount: Blood samples will be analyzed and stored without any personal identifying information of the participant to protect their privacy. However, should any lab tests show abnormalities, study staff will inform the participant, provide context and clarification, and instruct them to follow up with their healthcare provider or help them identify appropriate medical care if they do not have a primary provider.

The research team, led by Dr. Annie Antar at Johns Hopkins School of Medicine —with major funding provided by amfAR— is looking to recruit a nationally-representative cohort of PLHIV who are 18 years of age or older, reside in any of the 48 contiguous US states and either:
--Are HIV+ and have no history of a COVID-19 diagnosis or positive test result
Or
--Are HIV+ and have contracted COVID-19 for the first time and contact the study within the 4 weeks following the onset of symptoms, testing positive or receiving a clinical diagnosis.

For questions or comments, contact this team at hello@longcovidjustice.org.

Enroll now!
https://www.covidrecoverystudy.org

07/14/2022

"Our study suggests that as these highly transmissible subvariants continue to expand around the globe, they will lead to more breakthrough infections in people who are vaccinated and boosted with currently available mRNA vaccines," Ho said.

Newest Omicron subvariants can evade boosters and antibody therapies

BA.4 and BA.5—which now cause more than 70% of US cases—are 4 times more resistant to 3 vaccine doses than BA.2 is, and only 1 of 19 monoclonal antibodies tested showed efficacy against those subvariants.